Eli Lilly Accounts Receivable Derecognized decreased by 7.7% to $440.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.1%, from $419.20M to $440.40M. Over 4 years (FY 2020 to FY 2024), Accounts Receivable Derecognized shows a downward trend with a -13.6% CAGR.
accounts_receivable_derecognized| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $694.30M | $617.40M | $550.50M | $449.50M | $408.60M | $356.80M | $422.10M | $423.40M | $429.50M | $403.80M | $431.90M | $399.00M | $364.10M | $419.20M | $421.60M | $410.80M | $477.20M | $440.40M |
| QoQ Change | — | -11.1% | -10.8% | -18.3% | -9.1% | -12.7% | +18.3% | +0.3% | +1.4% | -6.0% | +7.0% | -7.6% | -8.7% | +15.1% | +0.6% | -2.6% | +16.2% | -7.7% |
| YoY Change | — | — | — | — | -41.1% | -42.2% | -23.3% | -5.8% | +5.1% | +13.2% | +2.3% | -5.8% | -15.2% | +3.8% | -2.4% | +3.0% | +31.1% | +5.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.